AI
NKTR icon

Acuitas Investments’s Nektar Therapeutics NKTR Stock Holding History

Acuitas Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,096
Closed -$1.43M – 101
2024
Q3 		$1.43M Buy
73,096
+14,436
+25% +$275K 0.64% 64
2024
Q2 		$1.09M Sell
58,660
-26,714
-31% -$563K 0.58% 65
2024
Q1 		$1.2M Buy
85,374
+24,627
+41% +$258K 0.6% 62
2023
Q4 		$515K Buy
60,747
+12,650
+26% +$95.8K 0.27% 95
2023
Q3 		$430K Sell
48,097
-3
-0% -$29 0.25% 88
2023
Q2 		$415K Buy
+48,100
New +$513K 0.24% 94

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Acuitas Investments's NKTR Position: Q4 2024 in Review

Acuitas Investments sold out of Nektar Therapeutics (NKTR) in Q4 2024, closing a stake of 73,096 shares — an estimated $1.43M sold.

Acuitas Investments first reported a position in NKTR in Q2 2023 and held it in 6 quarters. The position peaked at $1.43M in Q3 2024. 143 funds tracked by Wall St. Rank hold NKTR as of Q4 2024.

  • Acuitas Investments reported no remaining Nektar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 73,096 Nektar Therapeutics shares in Q4 2024, an estimated $1.43M.
  • Acuitas Investments first reported a position in Nektar Therapeutics in Q2 2023 and held it in 6 quarters.
  • Acuitas Investments's Nektar Therapeutics position peaked at $1.43M in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.